连花清咳颗粒

Search documents
以岭药业(002603) - 2025年8月28日投资者关系活动记录表
2025-08-28 08:34
编号:20250828 证券代码: 002603 证券简称:以岭药业 石家庄以岭药业股份有限公司投资者关系活动记录表 治疗胃肠型感冒藿夏感冒颗粒、治疗肌萎缩侧索硬化症参蓉颗粒、治疗小儿支 气管炎的连花清咳颗粒、治疗感冒气虚证的连花玉屏颗粒 5 个品种处于临床 II 期阶段。 | 投 | 资 | 者 | 关 | □特定对象调研 | □ | 分析师会议 | 系 | 活 | 动 | 类 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | □ | 媒体采访 | 业绩说明会(电话会议) | ☑ | 别 | | | | | | | | □ | 新闻发布会 | □ | 路演活动 | | | | | | | | | □ | 现场参观 | | | | | | | | | | | □ | 其他 | (请文字说明其他活动内容) | | | | | | | | | | 参 | 与 | 单 | 位 | 华创证券、国盛证券、开源证券、建投证券、中金证券、兴业证券、海通证券、 | | | | | | | | 名 | 称 | 及 | 人 | 中信证券 ...
以岭药业2024年研发占比14% 保持创新研发投入加码可持续发展
Zheng Quan Zhi Xing· 2025-04-28 16:10
Core Viewpoint - Yiling Pharmaceutical (002603) emphasizes its commitment to technological innovation as a core competitive advantage, with R&D investment exceeding 900 million yuan, accounting for 13.94% of its revenue, significantly higher than the industry average [1][4]. R&D Investment - From 2019 to 2023, Yiling Pharmaceutical's total R&D investment approached 4 billion yuan, demonstrating a consistent growth trend [1][3]. - The company has a substantial patent portfolio, with 884 effective patents as of the end of 2024, creating a strong technological barrier [4]. Product Pipeline and Innovation - Yiling Pharmaceutical has developed 17 patented traditional Chinese medicines (TCM), with 11 included in the national medical insurance directory and 5 in the essential drug list [4]. - The company has a rich pipeline of innovative TCM products, with 2 first-class new drugs nearing market launch and several others in various clinical stages [5][6]. Clinical Research and Achievements - The company has successfully completed five evidence-based medical studies focusing on cardiovascular disease prevention, receiving an "excellent" performance evaluation [4]. - Research results have been published in prestigious international medical journals, significantly impacting the medical community [4]. Business Diversification - Yiling Pharmaceutical is expanding into biopharmaceuticals and health industries, creating a synergistic development model that includes patented TCM, biopharmaceuticals, and health products [7]. - The health product line includes various series targeting different health needs, with one proprietary health food product approved for production in 2024 [7].